PT  - JOURNAL ARTICLE
AU  - Kox, Matthijs
AU  - Frenzel, Tim
AU  - Schouten, Jeroen
AU  - van de Veerdonk, Frank L.
AU  - Koenen, Hans J.P.M.
AU  - Pickkers, Peter
AU  - ,
TI  - COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients
AID  - 10.1101/2020.04.03.20049080
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.03.20049080
4099  - http://medrxiv.org/content/early/2020/04/16/2020.04.03.20049080.short
4100  - http://medrxiv.org/content/early/2020/04/16/2020.04.03.20049080.full
AB  - At the end of March 2020, there were in excess of 800.000 confirmed cases of coronavirus disease 2019 (COVID-19) worldwide. Several reports suggest that, in severe cases, COVID-19 may cause a hyperinflammatory “cytokine storm”. However, unlike SARS-CoV infection, high levels of anti-inflammatory mediators have also been reported in COVID-19 patients. One study reported that 16% of COVID-19 patients who died developed secondary infection, which might indicate an immune-suppressed state. We explored kinetics of mHLA-DR expression, the most widely used marker of innate immune suppression in critically ill patients, in COVID-19 patients admitted to the ICU.Twenty-four confirmed COVID-19 patients were included, of which 75% was male and 79% had comorbidities. All patients were mechanically ventilated and exhibited large high levels of inflammatory parameters such as CRP and PCT. Although mHLA-DR expression levels in COVID-19 patients were lower than those observed in healthy subjects, the extent of suppression was less pronounced than observed in bacterial septic shock patients. mHLA-DR expression kinetics revealed no change over time. None of the COVID-19 patients developed a secondary infection.In conclusion, despite a pronounced inflammatory response, mHLA-DR expression kinetics indicate more moderate innate immune suppression in COVID-19 patients compared with bacterial septic shock patients. These data signify that innate immune suppression as a negative feedback mechanism following PAMP-induced inflammation appears less pronounced in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was internally funded by the participating departments.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in the article.